{"id":"NCT01807520","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-20","primaryCompletion":"2017-01-03","completion":"2017-01-03","firstPosted":"2013-03-08","resultsPosted":"2018-03-13","lastUpdate":"2018-03-13"},"enrollment":198,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Nail Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["AIN457"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":["placebo secukinumab"]}],"arms":[{"label":"Secukinumab (AIN457) 150 mg","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 300 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.","primaryOutcome":{"measure":"Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment","timeFrame":"Baseline, 16 weeks","effectByArm":[{"arm":"AIN457 150 mg","deltaMin":-38.4,"sd":4.54},{"arm":"AIN457 300 mg","deltaMin":-46.1,"sd":3.43},{"arm":"Placebo","deltaMin":-11.7,"sd":4.28}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":40,"countries":["United States","Australia","Belgium","Czechia","Denmark","Germany","Greece","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":96},"commonTop":["Nasopharyngitis","Psoriasis","Upper respiratory tract infection","Headache","Back pain"]}}